Fastnet's Amryt takeover aims to address $1.5 billion market opportunity

31 March 2016

Irish company Fastnet Equity (LSE: FAST), which last year announced a switch of focus from oil exploration to pharmaceuticals, is seeking to complete a £29.6 million ($42.2 million) takeover of orphan drug development firm Amryt Pharmaceuticals.

As it detailed its proposed acquisition on Wednesday, Fastnet also announced that it planned to raise £10 million through a share placing to help develop Episalvan (birch bark extract, a promising drug for the rare skin disorder epidermolysis bullosa.

Fastnet will also change its name to Amryt Pharma plc following the acquisition and begin trading under the new tickers “AMYT” (AIM) and “AYP” (ESM).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK